Ascendis Pharma Stock Price, News & Analysis

Ascendis Pharma (Nasdaq: ASND) will host an online event on June 1, 2021, to raise awareness for World Hypopara Awareness Day. The event will feature a live reading by bestselling children's author Ariana Feiner, known for her short film documentary, A Story of Courage, which has won 24 international awards. This initiative aims to inspire and support those affected by hypoparathyroidism, a rare condition affecting approximately 200,000 patients in the US and other countries. The event is accessible via www.astoryofcourage.live.

Ascendis Pharma (ASND) announced Q1 2021 results, reporting a net loss of €62.8 million, or €1.17 per share, with revenue decreasing to €0.7 million from €2.2 million year-on-year. The decline in revenue was attributed to lower license revenue and clinical supplies sales. R&D expenses surged to €88.1 million, up from €57.5 million, driven by increased personnel costs and ongoing product development. Cash reserves stood at €771.1 million. The PDUFA date for TransCon hGH is set for June 25, 2021, with a commercial launch anticipated in Q3 2021.

Ascendis Pharma A/S (ASND) announced a conference call on May 27, 2021, at 4:30 p.m. ET to discuss Q1 2021 financial results and provide a business update. The conference will be accessible via a live webcast on the company's website. Ascendis is focused on developing therapies using its TransCon technology for rare diseases and oncology. The company aims to address unmet medical needs and is expanding into new therapeutic areas. The press release highlights Ascendis' commitment to impactful patient care.

Ascendis Pharma has filed a Clinical Trial Notification (CTN) in Japan for the phase 3 PaTHway Japan Trial of TransCon PTH, a potential hormone replacement therapy for hypoparathyroidism. This trial aims to evaluate the safety and efficacy of TransCon PTH in adult patients, contributing to a global program for marketing authorization. The therapy addresses a significant unmet need for patients suffering from this rare endocrine disorder, affecting approximately 200,000 individuals in the U.S., Europe, Japan, and South Korea.

Ascendis Pharma (Nasdaq: ASND) reported preliminary 58-week results from the open-label extension of the PaTH Forward Trial for TransCon PTH, a treatment for hypoparathyroidism. The results show that 91% of the 58 participants were off standard care, maintaining normal urinary calcium levels and experiencing improved quality of life. TransCon PTH was well-tolerated, with no serious adverse events reported. Ascendis plans to conduct a phase 3 trial in Japan and expects topline results from a related study in Q4 2021.

Ascendis Pharma A/S (Nasdaq: ASND) announced the presentation of data for TransCon PTH at two medical conferences. The 48th annual meeting of the European Calcified Tissue Society is set for May 6-8, 2021, followed by the 23rd European Congress of Endocrinology from May 22-26, 2021. The results from the PaTH Forward Trial suggest that TransCon PTH may serve as a first-line hormone replacement therapy for hypoparathyroidism. Oral presentations at both conferences highlight the significance of these findings, which could impact treatment options in endocrinology.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021. Company executives will present a business overview and update on its pipeline programs. The event will be held virtually at 4:15 p.m. Eastern Time. A live audio webcast will be accessible on the Company’s website and will be available for replay for 30 days post-event. Ascendis Pharma focuses on utilizing its TransCon technologies to develop therapies for unmet medical needs, currently featuring a pipeline in endocrinology and oncology.

Ascendis Pharma A/S (Nasdaq: ASND) has announced presentations featuring TransCon hGH (lonapegsomatropin) at two medical conferences: Pediatric Endocrinology Nursing Society (PENS) from April 21-23 and Pediatric Endocrine Society (PES) from April 30-May 3, 2021. The company will present two-year follow-up data on the efficacy and safety of lonapegsomatropin in children with growth hormone deficiency (GHD), alongside a model for estimating average IGF-1 levels. The presentations aim to support healthcare providers in managing patients post-regulatory approval.

Ascendis Pharma A/S (Nasdaq: ASND) announced participation in the J.P. Morgan 10th Annual Napa Valley Biotech Forum on March 30, 2021, at 4:00 p.m. ET. The forum will be virtual, allowing company executives to present a business overview and updates on their pipeline programs. The event underscores Ascendis' commitment to expanding its portfolio of rare disease and oncology product candidates using its innovative TransCon technologies. A live audio webcast will be available on the company’s website, with a replay accessible for 30 days post-event.